| Alemtuzumab. | |
| | |
MedLine Citation:
|
PMID: 19899240 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
When the CAMMS 223 trial was formally reported in the New England Journal of Medicine in October of 2008, huge interest was generated in the media, among people with multiple sclerosis (MS) and their relatives and friends. The suggestion that a therapy Campath-1H (now known as alemtuzumab) was available which surpassed the effectiveness of current standard treatments, provided by infusions given at yearly intervals or even less frequently and which appeared to reduce the accumulation of disability was hailed in the lay press as virtually a 'cure'. The paper in this edition of the journal (Spotlight on Alemtuzumab, page 77) provides a more realistic account of alemtuzumab, describing the Cambridge experience, tracking the history of Campath-1H, one of the oldest humanized monoclonal antibodies, from its origin in the laboratory to its future licensing in the clinical management of people with MS. |
| | |
Authors:
|
D Bates |
Publication Detail:
|
Type: Comment; Editorial; Introductory Journal Article |
Journal Detail:
|
Title: International MS journal / MS Forum Volume: 16 ISSN: 1352-8963 ISO Abbreviation: Int MS J Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-11-09 Completed Date: 2009-12-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9804403 Medline TA: Int MS J Country: England |
Other Details:
|
Languages: eng Pagination: 75-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
therapeutic use* Antibodies, Monoclonal / therapeutic use* Antibodies, Neoplasm / adverse effects, therapeutic use* Disability Evaluation Humans Multiple Sclerosis, Chronic Progressive / drug therapy* Multiple Sclerosis, Relapsing-Remitting / drug therapy* Randomized Controlled Trials as Topic / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Antibodies, Monoclonal; 0/Antibodies, Neoplasm; 0/alemtuzumab |
| Comments/Corrections | |
Comment On:
|
Int MS J. 2009 Sep;16(3):77-81
[PMID:
19878629
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reprint of mutation of the fucose-specific beta1,3 N-acetylglucosaminyltransferase LFNG results in a...
Next Document: Influenza A/H1N1 virus--old and new